Rethinking placebo-controlled clinical trials in psychedelic therapies for psychiatric illness.

The authors argue that standard placebo-controlled trial designs are poorly suited to psychedelic therapies because the intense subjective effects of psychedelics make blinding nearly impossible and may introduce confounding expectations. They propose alternative methodological approaches, such as active placebo controls, comparative effectiveness designs, and pragmatic trials, to better evaluate the efficacy and safety of psychedelic-assisted treatments for psychiatric conditions.

Study at a glance

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.